LEADER 03323nam 2200613 a 450 001 9910808405203321 005 20240313154333.0 010 $a1-118-51700-8 010 $a1-299-24266-9 010 $a1-118-51701-6 035 $a(CKB)2670000000335822 035 $a(EBL)1132837 035 $a(OCoLC)829459871 035 $a(SSID)ssj0000833771 035 $a(PQKBManifestationID)11411977 035 $a(PQKBTitleCode)TC0000833771 035 $a(PQKBWorkID)10936154 035 $a(PQKB)10913476 035 $a(MiAaPQ)EBC1132837 035 $a(Au-PeEL)EBL1132837 035 $a(CaPaEBR)ebr10667420 035 $a(CaONFJC)MIL455516 035 $a(PPN)178990264 035 $a(EXLCZ)992670000000335822 100 $a20121126d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNonclinical safety assessment $ea guide to international pharmaceutical regulations /$fedited by William J. Brock, Kenneth L. Hastings, Kathy M. McGown 205 $a1st ed. 210 $aChichester, West Sussex $cJohn Wiley & Sons$d2013 215 $a1 online resource (487 p.) 300 $aDescription based upon print version of record. 311 $a0-470-74591-6 320 $aIncludes bibliographical references and index. 327 $aIntroduction to the development of drugs / Kathy McGown -- ICH / Ken Hastings -- USFDA / Bill Brock -- Latin America : MERCOSUR countries / Cristiana Leslie Corra -- Canada / Mark T. Goldberg -- EMEA / Adam Woolley -- Africa / Fariza Feraoun -- China / Lijie Fu -- Japan / Kazuichi Nakamura -- India / K.S. Rao -- Australia / Doug Francis -- Chronic repeat dose testing / Shana Azri-Meehan -- Carcinogenicity / James Popp -- Genotoxicity / Mark Powley -- Developmental and reproductive toxicology / Robert Parker -- Juvenile testing and pediatric claim / Melissa Tassinari -- Immunotoxicology / Leigh Ann Burns Naas -- Biologics / Chris Ellis -- Vaccines / Robert House -- Phototoxicity and photocarcinogenicity / Chris Sambuco -- Degradants, impurities excipients, and metabolites / Bob Osterberg. 330 $aBringing a new drug to market is a costly time-consuming process. Increased regional and international regulation over the last twenty years, while necessary, has only served to amplify these costs. In response to this escalation, developmental strategies have shifted towards a more global approach. In order to create the most cost-effective and safe processes, it is critical for those bringing drugs to market to understand both the globally accepted regulations and the local variations. Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations provides a practi 606 $aDrug development$xInternational cooperation 606 $aDrugs$xToxicology$xInternational cooperation 615 0$aDrug development$xInternational cooperation. 615 0$aDrugs$xToxicology$xInternational cooperation. 676 $a615.1/901 701 $aBrock$b William J$0292040 701 $aHastings$b Kenneth L$01603351 701 $aMcGown$b Kathy M$01603352 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910808405203321 996 $aNonclinical safety assessment$93927682 997 $aUNINA LEADER 00957nam0 22002651i 450 001 UON00232594 005 20231205103509.613 100 $a20030730d1935 |0itac50 ba 101 $agre 102 $aGR 105 $a|||| 1|||| 200 1 $aˆE ‰Psychopathologia tou Ougou Phoskolou$fSp. N. Limperatou 210 $aAthenai$cKasigone$d1935 215 $a93 p.$d20 cm. 606 $aFoscolo Ugo$3UONC042620$2FI 620 $aGR$dAtene$3UONL000203 676 $a850$cLetteratura italiana$v21 700 1$aLIBERATOS$bSp.$3UONV140977$0687372 712 $aKasigones Angelos$3UONV271239$4650 801 $aIT$bSOL$c20250606$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00232594 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI FONDO ZORAS 0631 $eSI EO 34742 5 0631 996 $aPsychopathologia tou Ougou Phoskolou$91233524 997 $aUNIOR LEADER 01494nam 2200421z- 450 001 9910547688003321 005 20220219 010 $a1000133709 035 $a(CKB)5840000000005219 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/78428 035 $a(oapen)doab78428 035 $a(EXLCZ)995840000000005219 100 $a20202202d2022 |y 0 101 0 $ager 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aEmanzipatorisches Wohnen$eMyra Warhaftigs Beitrag zur Internationalen Bauausstellung 1984/87 210 $aKarlsruhe$cKIT Scientific Publishing$d2022 215 $a1 online resource (140 p.) 311 08$a3-7315-1105-3 330 $aThis monograph illuminates Myra Warhaftig's (1930-2008) architectural contribution to the 1984/87 International Building Exhibition in Berlin. The focus is on the life and work of a Jewish female architect in Germany, in which scientific, social and ethical demands are uniquely combined. 517 $aEmanzipatorisches Wohnen 606 $aArchitecture$2bicssc 610 $aArchitecture 610 $aArchitektur 610 $aEmancipation 610 $aEmanzipation 610 $aIBA 610 $aMyra 610 $aWarhaftig 615 7$aArchitecture 700 $aKrüger$b Anna$4auth$01294375 906 $aBOOK 912 $a9910547688003321 996 $aEmanzipatorisches Wohnen$93023168 997 $aUNINA